Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 94

1.

Effect of simvastatin on CSF Alzheimer disease biomarkers in cognitively normal adults.

Li G, Mayer CL, Morelli D, Millard SP, Raskind WH, Petrie EC, Cherrier M, Fagan AM, Raskind MA, Peskind ER.

Neurology. 2017 Sep 19;89(12):1251-1255. doi: 10.1212/WNL.0000000000004392. Epub 2017 Aug 18.

PMID:
28821686
2.

Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.

Lafeber M, Spiering W, Visseren FL, Grobbee DE, Bots ML, Stanton A, Patel A, Prabhakaran D, Webster R, Thom S, Rodgers A; UMPIRE investigators.

Eur J Prev Cardiol. 2017 Jun;24(9):951-961. doi: 10.1177/2047487317695616. Epub 2017 Mar 8.

PMID:
28436727
3.
4.

Relation of Variability of Low-Density Lipoprotein Cholesterol and Blood Pressure to Events in Patients With Previous Myocardial Infarction from the IDEAL Trial.

Bangalore S, Fayyad R, Messerli FH, Laskey R, DeMicco DA, Kastelein JJ, Waters DD.

Am J Cardiol. 2017 Feb 1;119(3):379-387. doi: 10.1016/j.amjcard.2016.10.037. Epub 2016 Nov 4.

PMID:
27939230
5.

Chronotherapy versus conventional statins therapy for the treatment of hyperlipidaemia.

Izquierdo-Palomares JM, Fernandez-Tabera JM, Plana MN, Añino Alba A, Gómez Álvarez P, Fernandez-Esteban I, Saiz LC, Martin-Carrillo P, Pinar López Ó.

Cochrane Database Syst Rev. 2016 Nov 26;11:CD009462. Review.

PMID:
27888640
6.

Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis.

Gili S, Grosso Marra W, D'Ascenzo F, Lonni E, Calcagno A, Cannillo M, Ballocca F, Cerrato E, Pianelli M, Barbero U, Mancone M, DiNicolantonio JJ, Lavie CJ, Omedè P, Montefusco A, Bonora S, Gasparini M, Biondi-Zoccai G, Moretti C, Gaita F.

Eur Heart J. 2016 Dec 21;37(48):3600-3609. doi: 10.1093/eurheartj/ehv734. Epub 2016 Feb 6. Review.

PMID:
26851703
7.

Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease.

Lafeber M, Webster R, Visseren FLj, Bots ML, Grobbee DE, Spiering W, Rodgers A; Programme to Improve Life and Longevity (PILL) Collaborative Group.

Eur J Prev Cardiol. 2016 Aug;23(12):1289-97. doi: 10.1177/2047487315624523. Epub 2016 Jan 7.

PMID:
26743587
8.

2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis?

Bangalore S, Fayyad R, Kastelein JJ, Laskey R, Amarenco P, DeMicco DA, Waters DD.

Am J Med. 2016 Apr;129(4):384-91. doi: 10.1016/j.amjmed.2015.10.024. Epub 2015 Nov 6.

PMID:
26551986
9.

Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.

Bohula EA, Giugliano RP, Cannon CP, Zhou J, Murphy SA, White JA, Tershakovec AM, Blazing MA, Braunwald E.

Circulation. 2015 Sep 29;132(13):1224-33. doi: 10.1161/CIRCULATIONAHA.115.018381. Epub 2015 Sep 1.

10.

Testing the Short-Term Efficacy of a Lipid-Lowering Nutraceutical in the Setting of Clinical Practice: A Multicenter Study.

Cicero AF, Derosa G, Pisciotta L, Barbagallo C; SISA-PUFACOL Study Group.

J Med Food. 2015 Nov;18(11):1270-3. doi: 10.1089/jmf.2015.0024. Epub 2015 Aug 14.

11.

Dyslipidemia and cardiovascular disease in women.

Cífková R, Krajčoviechová A.

Curr Cardiol Rep. 2015 Jul;17(7):609. doi: 10.1007/s11886-015-0609-5. Review.

PMID:
26026998
12.

Impact of Switching From High-Efficacy Lipid-Lowering Therapies to Generic Simvastatin on LDL-C Levels and LDL-C Goal Attainment Among High-Risk Primary and Secondary Prevention Populations in the United Kingdom.

Cao X, Ejzykowicz F, Ramey DR, Sajjan S, Ambegaonkar BM, Mavros P, Tunceli K.

Clin Ther. 2015 Apr 1;37(4):804-15. doi: 10.1016/j.clinthera.2014.12.019. Epub 2015 Jan 24.

PMID:
25626487
13.

Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study.

Ballantyne CM, Hoogeveen RC, Raya JL, Cain VA, Palmer MK, Karlson BW; GRAVITY Study Investigators.

Atherosclerosis. 2014 Jan;232(1):86-93. doi: 10.1016/j.atherosclerosis.2013.10.022. Epub 2013 Nov 1.

PMID:
24401221
14.

The effect of red yeast rice (Monascus purpureus) in dyslipidemia and other disorders.

Yang CW, Mousa SA.

Complement Ther Med. 2012 Dec;20(6):466-74. doi: 10.1016/j.ctim.2012.07.004. Epub 2012 Aug 17. Review.

PMID:
23131380
15.

Ezetimibe/simvastatin 10/40 mg versus atorvastatin 40 mg in high cardiovascular risk patients with primary hypercholesterolemia: a randomized, double-blind, active-controlled, multicenter study.

Hing Ling PK, Civeira F, Dan AG, Hanson ME, Massaad R, De Tilleghem Cle B, Milardo C, Triscari J.

Lipids Health Dis. 2012 Jan 31;11:18. doi: 10.1186/1476-511X-11-18.

16.

Pitavastatin: clinical effects from the LIVES Study.

Teramoto T.

Atheroscler Suppl. 2011 Nov;12(3):285-8. doi: 10.1016/S1567-5688(11)70888-1. Review.

PMID:
22152283
17.

Pitavastatin: novel effects on lipid parameters.

Chapman MJ.

Atheroscler Suppl. 2011 Nov;12(3):277-84. doi: 10.1016/S1567-5688(11)70887-X. Review.

PMID:
22152282
18.

Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.

Nicholls SJ, Brewer HB, Kastelein JJ, Krueger KA, Wang MD, Shao M, Hu B, McErlean E, Nissen SE.

JAMA. 2011 Nov 16;306(19):2099-109. doi: 10.1001/jama.2011.1649.

PMID:
22089718
19.

Comparative efficacy of pitavastatin and simvastatin in high-risk patients: a randomized controlled trial.

Eriksson M, Budinski D, Hounslow N.

Adv Ther. 2011 Sep;28(9):811-23. doi: 10.1007/s12325-011-0056-7. Epub 2011 Aug 25.

PMID:
21874538
20.

Long-term efficacy of pitavastatin versus simvastatin.

Eriksson M, Budinski D, Hounslow N.

Adv Ther. 2011 Sep;28(9):799-810. doi: 10.1007/s12325-011-0057-6. Epub 2011 Aug 25.

PMID:
21874537

Supplemental Content

Loading ...
Support Center